Uni­cy­cive gets a CRL for chron­ic kid­ney dis­ease pill as third-par­ty pro­duc­tion is­sues linger

Uni­cy­cive Ther­a­peu­tics’ phos­phate binder drug has failed to se­cure FDA ap­proval for cer­tain chron­ic kid­ney dis­ease (CKD) pa­tients, mark­ing an­oth­er hitch in its goal to …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER